Navigation Links
Coherus anuncia início do estudo Fase 3 do CHS-0214 (Biossimilar Investigativo do Etanercept) em psoríase crônica em placas (RaPsOdy)
Date:7/16/2014

REDWOOD CITY, California, 16 de julho de 2014 /PRNewswire/ -- A Coherus BioSciences, Inc. anunciou o início do seu estudo Fase 3 do CHS-0214, uma proposta de biossimilar do etanercept (Enbrel®) na psoríase crônica em placas (a RaPsOdy). Este anúncio acompanha o recente início de um estudo Fase 3 do CHS-0214 em artrite reumatoide. O estudo psoríase Fase 3 é um estudo mundial de 48 semanas, randomizado, duplo-cego, com controle ativo, de grupos paralelos, multicêntrico em indivíduos com psoríase ativa crônica em placas e não expostos à terapia biológica sistêmica. O estudo procurará demonstrar a biossimilaridade entre o CHS-0214 e o Enbrel® em termos de eficácia, segurança e imunogenicidade. O endpoint primário de eficácia se baseia no percentual de melhoria no Psoriasis Area and Severity Index, PASI (Índice de Área e Severidade da Psoríase) em 12 semanas.

"O início do estudo Fase 3 da RaPsOdy é um passo importante em direção à nossa meta de aumentar o acesso ao etanercept biossimilar para pacientes em todo o mundo", disse Barbara Finck, M.D., diretora médica da Coherus. "Representa um estudo fundamental no desenvolvimento clínico mundial para o CHS-0214 e, em caso positivo, dará apoio às nossas aplicações de marketing na Europa, Estados Unidos e em uma série de outros países."

"Com base em nossa avaliação da similaridade farmacocinética analítica, não clínica e clínica desta molécula, acreditamos que ela atenda aos rigorosos critérios internos para o início do nosso segundo estudo Fase 3 em 2014", disse Denny Lanfear, CEO da Coherus. "Em conjunto com a nossa parceira Baxter<
'/>"/>

SOURCE Coherus BioSciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
2. Coherus anuncia que CHS-0214 (biosimilar etanercept propuesto) supera punto final primario en decisivo estudio clínico farmacocinético
3. Coherus Biosciences als Präsentator zur J.P. Morgan Annual Healthcare Conference 2014 eingeladen
4. Coherus Biosciences Invited to Present at 2014 J.P. Morgan Annual Healthcare Conference
5. Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy)
6. L.S.E. (Barcelona) anuncia la primera financiación del antiplaquetario NmC por inversores españoles y suizos
7. RPS anuncia a Jonathan M. Fishbein, MD, como vicepresidente ejecutivo y jefe médico
8. RPS anuncia Jonathan M. Fishbein, MD como vice-presidente executivo e diretor médico
9. GenScript Anuncia Exposição Itinerante Junto com a Open Monoclonal Technology, Inc.
10. GenScript anuncia una muestra itinerante conjunta con Open Monoclonal Technology, Inc.
11. GenScript anuncia un programa conjunto con Open Monoclonal Technology, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX ), a late-stage ... Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical ... investor conferences in September. , ... LLC Emerging Growth Conference in New ... President & Chief Executive Officer, will present a corporate ...
(Date:8/31/2015)... Aug. 31, 2015 Regen BioPharma, Inc. (OTCBB: ... a novel means of delivering its patented (US ... liver tumors utilizing a clinically approved formulation as ... hurdles with gene silencing therapeutics in which the ... the whole body.  By utilizing a local delivery ...
(Date:8/31/2015)... FLINT, Mich. , Aug. 31, 2015  Diplomat Pharmacy, ... pharmacy, has announced that Phil Hagerman , Chairman & ... four upcoming investor conferences. Mr. Hagerman and ... 2015 Healthcare Conference in Boston on ... Mr. Hagerman and Mr. Whelan are also scheduled to participate ...
Breaking Medicine Technology:Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Diplomat to Participate in Upcoming Investor Conferences 2
... March 28, 2011 Accuray Incorporated (Nasdaq: ARAY ... today that its management is scheduled to present at the ... Tuesday, April 5, 2011 at 10:00 a.m. ET/7:00 a.m. PT. ... available online from the investor relations page of the Company,s ...
... The U.S. Food and Drug Administration is warning ... by Indo Pharma, S.A., of the Dominican Republic, because ... A and D. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... the product treats "hypo and avitaminosis, rickets, growth, dentition, ...
Cached Medicine Technology:Accuray Incorporated to Speak at 10th Annual Needham Healthcare Conference 2FDA Warns Consumers to Stop Using Soladek Vitamin Solution 2
(Date:8/31/2015)... TN (PRWEB) , ... August 31, 2015 , ... ... urgent care and accessible primary care, is enhancing its existing presence in Tennessee ... in Knoxville. The location is the company’s second in Knoxville, sixteenth in Tennessee, ...
(Date:8/31/2015)... KY (PRWEB) , ... August 31, 2015 , ... ... Wyoming, has selected ezDI’s computer-assisted coding (CAC) software for its Clinical Documentation Improvement ... engine, ezNLP, and a patent pending ICD-10 solution - ezCAC is an enterprise-level ...
(Date:8/31/2015)... ... ... The more hours young adults spend watching television each day, the greater ... a 15-year analysis by the University of Pittsburgh Graduate School of Public Health revealed. ... adulthood is an important time to intervene and promote less television viewing, according to ...
(Date:8/31/2015)... PA (PRWEB) , ... August 31, 2015 , ... ... than their peers may be at a greater risk for injury, potentially because ... behaviors, a University of Pittsburgh Graduate School of Public Health analysis discovered. ...
(Date:8/31/2015)... ... 2015 , ... With baseball season in full swing, many fans are already ... sports world. Fans desire nothing more than to see their favorite team take the ... those who are too young to really understand what all the fuss is about, ...
Breaking Medicine News(10 mins):Health News:State-of-the-Art Urgent Care Facility Opening in Knoxville 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 3Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 4Health News:Watching More TV as a Young Adult Predicts Obesity 2Health News:Watching More TV as a Young Adult Predicts Obesity 3Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 3Health News:New Children's Baseball Series Offers Young Fans a Way to Celebrate the World Series 2
... 15 million Americans are recruited annually to participate in clinical ... and most will be compensated for their participation. ... compensation for time and expenses; not as compensation for potential ... new study finds that volunteers have a very different view ...
... leads to success, study finds , FRIDAY, Dec. 4 ... self-weighing are among the most effective weight control strategies ... 130 adolescents about their weight-control strategies and lifestyle habits. ... not. The responses were grouped into four categories: , ...
... and surveillance urged for at-risk patient groups , FRIDAY, ... Ewing sarcomas and central nervous system tumors, carry the ... The study authors analyzed data from 12,795 five-year survivors ... in the Childhood Cancer Survivor Study. , The researchers ...
... take breast cancer drug, study finds , FRIDAY, Dec. 4 ... reason why only 6 percent of American women at high ... tamoxifen to prevent the disease, a new study finds. , ... benefits of tamoxifen, researchers at the University of Michigan Comprehensive ...
... , JACKSONVILLE, Fla., ... awards for their work in improving the health of Florida,s ... Florida,s 2009 Sapphire Award ceremony. , The Sapphire Award is ... have demonstrated excellence in addressing health disparities within their communities. ...
... , PARAMUS, N.J., Dec. 4 Movado Group Inc. (NYSE: ... Jewelers, Atlanta, Georgia, shared in a tribute on December 3, ... her stellar performance in the tournament. Melanie became the youngest ... http://www.newscom.com/cgi-bin/prnh/20091204/NY21184 ) , At a celebratory reception held ...
Cached Medicine News:Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Teens Lose More Weight Using Healthy Strategies 2Health News:High-Risk Women May Often Avoid Using Tamoxifen 2Health News:Top Nonprofits Honored for Improving Health of Floridians 2Health News:Top Nonprofits Honored for Improving Health of Floridians 3
... pressure sensor and continues to lead ... only sensor on the market that ... significantly improved maneuverability and pushability, it ... as well as a valuable clinical ...
... its professional AED offeringthe G3 Pro. ... ECG color display, provides manual override ... most advanced technology available to provide ... for emergency treatment of sudden cardiac ...
... The Littmann Electronic Stethoscope Model 4100WS features ... technology allowing you to reduce ambient noise ... eliminating critical body sounds. Three frequency modes ... and other body sounds: Bell (20-200 Hz), ...
... is a 3D quantitative echo system ... exams are performed. Intelligent design and ... revolutionary clinical performance and workflow. The ... data streams simultaneously and incorporates a ...
Medicine Products: